Heparin Sodium

CHENGDU, China, Dec. 19, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), Mr. Xin Zhanchang, Chairman of the Board of Directors of BGM Group and Chairman of Gansu Qilianshan Pharmaceutical Co., Ltd., led the sales team to visit their long-term strategic partner, Jointown Pharmaceutical Group. They were warmly welcomed by Mr. Liu Shulin, one of the founders and Honorary Vice Chairman of Jointown, along with Vice Chairman Mr. Liu Dengpan and other senior executives. The two sides held a cordial, productive meeting, further consolidating and deepening their strategic partnership. They also signed a strategic cooperation agreement for Qilianshan Pharmaceutical's licorice fluid extract and Gandixin (Compound Licorice Tablets) series products. Jointown Pharmaceutical Group, as a leading enterprise in China's pharmaceutical industry with the most extensive sales network, focuses on Western medicine, traditional Chinese medicine, and medical devices. It is committed to providing medical institutions, wholesale companies, and retail pharmacies with pharmaceutical products, logistics, and other value-added services. Meanwhile, BGM Group has demonstrated exceptional performance in the research, development, production, and operation of its "Qilianshan" brand pharmaceutical products. The long-standing partnership between the two companies stems from their outstanding achievements in their respective fields and a shared commitment to development philosophies. Over the years, BGM Group and Jointown have demonstrated a high degree of synergy in several areas. First, in product research, development, production, and sales, Qilianshan Pharmaceutical, a subsidiary of BGM Group, leverages its strong R&D capabilities and advanced production technologies under the "Qilianshan" brand. Combined with Jointown's comprehensive sales network and logistics distribution system, BGM's products have gained widespread recognition and acceptance in domestic and international markets. Second, BGM Group's rigorous quality testing system ensures product safety and quality. Both companies share a commitment to customer service excellence, offering comprehensive after-sales support and prioritizing consumer satisfaction. Lastly, in market expansion and brand building, the two companies maintain close collaboration, enhancing the influence of both the BGM and Jointown brands. During the meeting, the two parties engaged in in-depth discussions on market demand, quality control, and sales channel expansion for licorice-based products. They agreed that as the pharmaceutical industry continues to evolve, consumer demand for high-quality, high-efficiency pharmaceutical products will grow significantly. Both companies are dedicated to driving product innovation and quality improvement to meet the diverse needs of the market. In the presence of both teams, BGM Group and Jointown signed a strategic cooperation agreement for the licorice fluid extract and Gandixin (Compound Licorice Tablets) series products. This agreement marks a new milestone in their collaboration in the pharmaceutical sector, particularly in licorice-based products, with injecting strong momentum into their future development. Both parties reaffirmed their commitment to maintaining a close partnership and contributing to the prosperity and advancement of the pharmaceutical industry. This successful meeting between BGM Group and Jointown Pharmaceutical Group not only further solidified their strategic partnership but also paved the way for broader opportunities for future cooperation. Together, BGM Group and Jointown are poised to create an even brighter chapter in the pharmaceutical industry. Attendees of the meeting included Mr. Gong Li, Vice President of Jointown; Ms. Zhang Meiqin, General Manager of the Active Pharmaceutical Ingredients Division; Ms. Fu Qian, Deputy General Manager of Jiuxin Clinic under Jointown's Health Group; Mr. Liu Hui, Deputy General Manager of Quanqing Health; Mr. Wang Xiaoyan, Deputy General Manager of the Group Procurement Division; and Ms. Liu Yingmei, Sales Director of BGM Group. About BGM Group Ltd BGM Group Ltd,headquartered in Chengdu, China, is an innovative company dedicated to the fields of biopharmaceuticals, bio-extraction, and medical health. Our current product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. The oxytetracycline API not only provides raw materials for pharmaceutical companies to produce human antibiotics but also supports the global breeding and livestock industries to ensure the safety of poultry and seafood. The crude heparin sodium, after processing by downstream companies, is transformed into refined heparin sodium and heparin sodium injection solutions, which are major anticoagulants. Licorice preparations, such as compound licorice lozenges, are used as cough suppressants and supplied to retail pharmacies. For more information, visit the Company's website at: Forward-looking Statements This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook" and similar statements. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control, which may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. For investor and media inquiries, please contact: [email protected] SOURCE BGM Group Ltd WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SAN FRANCISCO, Dec. 3, 2024 /PRNewswire/ -- InsightRX – the leader in Bayesian model-informed precision dosing (MIPD) software – today announced it will attend the ASHP 2024 Midyear Clinical Meeting & Exhibition as both an exhibitor and presenter. The meeting is scheduled for Dec. 8-12 at the Ernest N. Morial Convention Center in New Orleans. ASHP 2024 is organized by the American Society of Health-System Pharmacists and will include vendor exhibits, educational sessions, poster presentations, and networking opportunities for pharmacy professionals. Representatives from the InsightRX team will be at booth 1340 in the exhibition hall (available on Monday Dec 9 and Tuesday Dec 10 from 11am - 3pm, and Wed Dec 11 from 11am - 2pm) to meet with visitors and discuss product updates, new features, and benefits of Bayesian MIPD adoption. Additionally, InsightRX Senior Director of Product & Customer Experience Jonathan Faldasz, PharmD, BCPS, will present a poster from the InsightRX team on Monday, Dec. 9, from 2-3:30 p.m. The title of the poster is Proposed Update to the Cockcroft-Gault Equation for Patients with Low Serum Creatinine: Results from a Massive Multi-Site Dataset. This study evaluated the accuracy of the Cockcroft-Gault equation–long regarded as the gold standard for estimating renal function–in patients with serum creatinine levels below 1 mg/dL. By analyzing data from nearly 100,000 patients, the InsightRX team identified significant inaccuracies in the equation's predictions for this population. In response, they developed a modified equation incorporating adjusted serum creatinine, which demonstrated greatly improved accuracy. The poster will detail these findings and their implications for clinical practice. Front and center will be demonstrations of a new feature to the Nova platform, InsightRX Gemini, designed to eliminate complexities of manual PK model selection. InsightRX Gemini automatically chooses the best-performing PK model for the patient, based on four common covariates, and was built analyzing approximately 400,000 vancomycin treatment courses contained in the Nova data lake. When compared to commonly available PK models (seen in "freeware" and various other applications), InsightRX Gemini: increases dosing accuracy for individual patients up to 47.2% increases precision by up to 25% decreases bias by up to 93% Overall, MIPD dosing activities have increased for a variety of therapeutic areas and hold promise for enhancing workflows and producing more accurate dosing and improved outcomes. In addition to vancomycin, InsightRX offers numerous other Drug Modules, which the team will also present at the exhibition. Several of these were highlighted in recent studies, thought leadership articles, and blog posts by the InsightRX team over the past year, including: Antifungals – Posaconazole is a pharmacotherapeutic pillar for prophylaxis and treatment of invasive fungal diseases. Dose individualization is critical to achieving adequate antifungal exposure associated with improved outcome. InsightRX validated an MIPD strategy for posaconazole for its fit-for-purpose, an important first step toward dosage optimization with the goal to improve antifungal treatment in clinical practice. Beta-lactams – Therapeutic drug monitoring (TDM) can improve PK/PD target attainment of beta-lactam levels and optimize dosing in vulnerable populations. There are still several barriers to widespread adoption of TDM of beta-lactams into routine clinical practice, however, beta-lactam TDM has great potential to improve patient care by optimizing antibiotic dosing, especially in high-risk populations. Solid organ transplant – Therapeutic drug monitoring is essential with tacrolimus, one of the key immunosuppressive agents used after solid organ transplant. Although most transplant centers rely on trough concentrations drawn immediately before the dose, evidence shows a poor correlation between tacrolimus trough concentrations and outcomes. A 2019 tacrolimus guidance document concludes that Bayesian estimation may be a better way to improve future tacrolimus TDM. Bone marrow transplant – Dose personalization improves patient outcomes for many drugs with a narrow therapeutic index and high inter-individuality variability, including busulfan. In a simulated study, InsightRX demonstrated that while area under the curve (AUC) estimates between the two methods showed good correlation, the maximum a posteriori Bayesian (MAP) approach led to higher target attainment for busulfan dosing. Anticoagulants – Heparin is a lifesaving mainstay of anticoagulation in patients at high risk of coagulation-related morbidity and mortality. Yet most hospitals struggle to keep their patients at a target heparin exposure, which can result in increased morbidity and mortality from both clotting and bleeding events. Several exciting advances in the use of MIPD for heparin would allow clinicians to better individualize therapy for each treatment course. Inflammatory bowel disease – Efficacy of infliximab in children with inflammatory bowel disease can be enhanced when serum concentrations are measured and further dosing is adjusted to achieve and maintain a target concentration. A recent collaborative study showed that a population pharmacokinetic model may help to predict an individual's infliximab dose requirement. "InsightRX has enjoyed a year of real growth and accomplishment and we're excited to meet with our colleagues at ASHP in New Orleans to discuss what we've learned and how we plan to continue improving dosing safety and accuracy," said Sirj Goswami, PhD, CEO and cofounder of InsightRX. "Model-informed precision dosing holds great promise for contributing to better clinical outcomes and operational efficiency." About InsightRX InsightRX is a healthcare technology company providing a cloud-based clinical decision support platform that applies quantitative pharmacology and AI to enhance therapeutic decision-making from phase I drug development to point of care. The company's platform provides an individualized, predictive understanding of a patient's response to treatment which enables an enhanced understanding of dose-effect response and toxicity for clinicians to improve medication effectiveness. Media Contact Michelle Noteboom Amendola Communications for InsightRX [email protected] SOURCE InsightRX WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED